Assessment of Synvisc treatment in osteoarthritis;Ocena leczenia preparatem Synvisc w osteoartrozie

Ortopedia Traumatologia Rehabilitacja

Volumn 5, Issue 3, 2003, Pages 379-390

  Andrzejewski, Tomasz ^a   Gołda, Waldemar ^b   Gruszka, Joanna ^c   Jander, Piotr ^c   Jeske, Piotr ^d   Jóźwik, Andrzej ^e   Kołban, Maciej ^f   Kukiełka, Radosław ^b   Kurpik, Mariusz ^c   Kwiatkowski, Krzysztof ^g   Marek, Maciej ^c   Morawski, Grzegorz ^c   Romaniuk, Wiesław ^h   Rusin, Zbigniew ⁱ   Ściński, Tadeusz ⁱ   Światłowski, Tomasz ⁱ   Szawczukiewicz, Władysław ^j   Tokarczuk, Krzysztof ^k   Wójcik, Bogdan ^c  

^a Szpital EuroMedicare   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Szpital Powiatowy ^*  (Poland)

^d Wielkopolskie Ctr Ortoped/Chir U   (Poland)

^e Srodmiejski Szpital Urazowy   (Poland)

^f POMERANIAN MEDICAL UNIVERSITY   (Poland)

^g MILITARY INSTITUTE OF MEDICINE   (Poland)

^h Wojskowy Szpital Kliniczny   (Poland)

ⁱ Centralny Osrodek Medycyny Sportowej   (Poland)

^j Szpital Kolejowy   (Poland)

^k 4 Wojskowy Szpit Klin z Poliklin   (Poland)

more..

Author keywords

Hyaluronian; Hylan G F 20; Knee; Osteoarthritis; Synvisc

Indexed keywords

BETAMETHASONE DIPROPIONATE; CYCLOOXYGENASE 2 INHIBITOR; HYALURONIC ACID; METHYLPREDNISOLONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; STEROID;

ANALGESIA; ANAMNESIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PAIN; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 2442473842     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Raynauld J et al: A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis and Cartilage 2002; 10, 506-517
2. Brand K.: The Role of Analgesics in the management of Ostheoarthritis Pain. Am J Therap. 2000; 7(2), 75-90
3. Bombardier C.: An Evidence-Based Evaluation of the gastroinestinal Safety of Coxibs. Excerpta Medica 2002; 89(6A), 3-9
4. The management of NSAID-associated G1 toxicity. A summary of the Sardinia Multidisciplinary Expert Statement. Am J Med 2001; 110: 79-100
5. Peyron J.: Viscosupplementation for the Treatment of Osteoarthritis of the Knee with Hyaluronian and Hylans: Rationale and State of the Art, Advances in Osteoarthritis 1999
6. Wobig M, et al.: The role of elastoviscosity in the efficacy of viscosupplementation with hylan G-F20 and a lower-molecular-weight hyaluronan. Clin Ther 1999; 21: 1549-62
7. Lussier A, Cividino AA, McFarlane CA, et al. Viscosuplementation with hylan for the treatment of osteoarthritis: Findings from clinical practice in Canada, Journal of Rheumatology 1996; 23: 1579-1585
8. Balazs EA, Denlinger JL. Viscosuplementation: A new concept in the treatment of ostearthritis. Journal of Rheumatology 1993; (suppl39)20: 3-9
9. Adams M.: An analysis of clinical studies of the use of crosslinked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatatol. 1993; 20 Suppl. 39, 16-8
10. Adams M., Atkinson M., Lussier A. et al.: The role of viscosupplementation with hylan G-F20 (Synvisc®) in the treatment of osteoarthritis of the knee: A Canadian multicenter trial comparing hylan G-F20 with non-steroidal anti-inflammatory drugs (NSDAIs) and NSDAIs alone. Ostearth. Cart. 1995; 3: 1129-226
11. Wobig M. et al.: Viscosupplementation with hylan G-F20: a 26-week controlled trial of efficacy and safety in osteoarthritic knee. Clin Ther 1998; 20: 410-23
12. Notice to Marketing Authorisation Holders Pharmacovigilance Guidelines, CPMP/PhVWP/108/99 corr. London, 29 January 1999
13. Summary of Product Characteristic - Data on file Wyeth sp.z o.o.
14. Kellgren J.H., Jeffrey M., Ball J.: Atlas of standard radiographs of arthritis. The epidemiology of chronic rheumatism. 1963; Vol 2. Blackwell Scentific Publications. Oxford
15. Scale D., Wobig M., Wolpert W.: Viscosuplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr. Ther. Res. 1994; 55: 220-232
16. Wobig M., Beks P., Dickhut A., Maier R., Vetter G.: Open-label Multicenter Trial of the Safety and Efficacy of Viscosupplementation with hylan G-F20 (Synvisc®) in Primary. Osteoarthritis of the Knee; J Clin Rheumatol. 1999; 6, 24-31
17. Dickson D., Hosie G. et al: Double-Blind, Placebo-Control Comparision of Viscosuplementation with Hylan G-F20 (Synvisc®) Against Diclofenac in Knee Osteoarthritis; J Clin Res 2001; 4: 41-52
18. Whelton A., Fort J., Puma J., Normandin D., Bello A., Verburg K.: Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial Of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients. Am J of Therapeutics 2001;8(2).